Sandoz launches MabThera, Enbrel biosimilars in the UK
Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Read More
Tag: Rixathon
Novartis’ MabThera biosimilar wins EU nod
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
